An interventional study of Wet Cupping Therapy in Asthma (Diagnosis), sponsored by Medipol University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 30 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Medipol University · Not applicable, Interventional, and Treatment
Among 133 studies in Asthma with a site in Turkey — 16 open to participants now, 21 under way, 5 of them phase 3. Asthma · Turkey.
Among the 133 studies in Asthma with a site in Turkey, this one is the 87th largest by enrollment of the 112 interventional ones, is one of 11 that started in 2025, is one of 50 with no phase, and was the 131st registered.
4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.
This study's enrollment of 52 is below the median of 78 across 3,341 interventional studies indexed under Asthma.
Browse Asthma studies →16 of the 133 studies in Asthma with a site in Turkey are open now, in 12 countries. Each count lists the studies.
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 146 take children under 18; 104 take healthy volunteers.
This study: 30 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →133 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 11 started in 2025.
Median enrollment 119 across the 112 interventional studies, 95 across the 21 observational. Of the 104 that completed or were terminated, 36 (35%) have results posted.
54 of 133 have an industry lead sponsor. The 10 most frequent:
Medipol University is the lead sponsor of 326 studies on the registry; 88 are open to participants now.
Medipol University has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
8 of the studies in Asthma with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07880145Hasan Kalyoncu UniversityEffects of Respiratory Muscle Strength Training in Children With Asthma | 2027-01 |
| NCT07320066Istanbul Esenyurt UniversityIMT in Asthma: Activity, Coping, Self-Management | 2027-01-01 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT07610447Bezmialem Vakif UniversityVR vs Treadmill Exercise in Children With Asthma | 2027-05-10 |
Among the 133 studies in Asthma with a site in Turkey, from their registry updates:
This study evaluated the effects of wet cupping therapy on immune modulation, pulmonary function, and quality of life in adults with asthma. A total of 52 participants aged 30 to 55 years were allocated to either a control group or a wet cupping therapy group. Participants in the wet cupping therapy group received two sessions of wet cupping therapy, at baseline and one month later. Participants in both groups underwent clinical assessments at baseline and at two months. Pulmonary function, asthma-related quality of life, asthma control, dyspnea, fatigue, anxiety, and depression were assessed in both groups. Selected inflammatory markers were assessed only in the wet cupping therapy group.
Inclusion Criteria:-
Exclusion Criteria:
Participants in the control group underwent pulmonary function testing at baseline and at two months and completed the study assessment scales at baseline and at the end of the study.
Participants received wet cupping therapy twice during the two-month study period, with the first session at baseline and the second session one month later. Pulmonary function testing and study assessments were performed at baseline and at two months.
Procedure: Wet Cupping Therapy
Wet cupping therapy was administered in two sessions at one-month intervals during the two-month study period. The procedure was performed at predefined anatomical points, including DU14, bilateral UB42, BL13, UB46. Negative-pressure cups were initially applied to the selected areas. After removal of the cups, superficial skin incisions were made using a sterile disposable No. 11 scalpel, followed by a second application of negative pressure for blood collection. Each session was planned to last approximately 30 minutes. The procedure was performed by a physician certified in wet cupping therapy.
Change in FVC From Baseline to 2 Months
Forced vital capacity (FVC) was assessed by spirometry. Change from baseline to 2 months was evaluated.
Time frame: Baseline and 2 months
Change in Asthma Quality of Life Questionnaire Score From Baseline to 2 Months
Asthma-related quality of life was assessed using the Asthma Quality of Life Questionnaire (AQLQ). Higher scores indicate better asthma-related quality of life.
Time frame: Baseline and 2 months
Change in COPD and Asthma Fatigue Scale Score From Baseline to 2 Months
Fatigue was assessed using the COPD and Asthma Fatigue Scale. Higher scores indicate greater fatigue severity.
Time frame: Baseline and 2 months
Change in FEV1 From Baseline to 2 Months
Forced expiratory volume in 1 second (FEV1) was assessed by spirometry. Change from baseline to 2 months was evaluated.
Time frame: Baseline and 2 months
Change in FEV1/FVC Ratio From Baseline to 2 Months
The FEV1/FVC ratio was assessed by spirometry. Change from baseline to 2 months was evaluated.
Time frame: Baseline and 2 months
Change in PEF From Baseline to 2 Months
Peak expiratory flow (PEF) was assessed by spirometry. Change from baseline to 2 months was evaluated.
Time frame: Baseline and 2 months
Change in Systemic Immune-Inflammation Index (SII) in the Wet Cupping Therapy Group From Baseline to 2 Months
The Systemic Immune-Inflammation Index (SII) was calculated from peripheral blood cell counts using platelet, neutrophil, and lymphocyte values. SII was assessed only in the wet cupping therapy group. The change in SII from baseline to 2 months was evaluated as an indicator of systemic immune-inflammatory status.
Time frame: Baseline and 2 months
Change in Systemic Inflammation Response Index (SIRI) in the Wet Cupping Therapy Group From Baseline to 2 Months
The Systemic Inflammation Response Index (SIRI) was calculated from peripheral blood cell counts using monocyte, neutrophil, and lymphocyte values. SIRI was assessed only in the wet cupping therapy group. The change in SIRI from baseline to 2 months was evaluated as an indicator of systemic inflammatory status.
Time frame: Baseline and 2 months
Change in Asthma Control Test Score From Baseline to 2 Months
Asthma control was assessed using the Asthma Control Test (ACT). The ACT is a 5-item questionnaire with a total score ranging from 5 to 25, with higher scores indicating better asthma control.
Time frame: Baseline and 2 months
Change in Modified Medical Research Council Dyspnea Scale Score From Baseline to 2 Months
Dyspnea was assessed using the modified Medical Research Council (mMRC) dyspnea scale. The scale ranges from 0 to 4, with higher scores indicating greater severity of breathlessness.
Time frame: Baseline and 2 months
Change in Hospital Anxiety and Depression Scale Scores From Baseline to 2 Months
Anxiety and depressive symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS). The HADS consists of 14 items, including 7 anxiety items and 7 depression items, each scored from 0 to 3. Higher subscale scores indicate greater anxiety or depressive symptoms.
Time frame: Baseline and 2 months
Change in Eosinophil Level in the Wet Cupping Therapy Group From Baseline to 2 Months
Peripheral blood eosinophil levels were assessed only in the wet cupping therapy group. Within-group changes from baseline to 2 months were evaluated.
Time frame: Baseline and 2 months
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Jan 2026, 7 months.
Of 599 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's 7 months is below that.
Counting every sponsor, half of 649 studies reached it within 23 months; a quarter within 10 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.